Medicine and Dentistry
Adverse Outcome
100%
Patient with Diabetes
100%
COVID-19
100%
Membrane Microparticle
100%
Vitronectin
100%
Virus Infection
66%
Infection
58%
Lipocortin 5
53%
Virus
46%
Cytokine
40%
Microvessel
40%
Diseases
40%
Internalization
40%
Lung
33%
Phosphatidylserine
26%
Serial Dilution
26%
Influenza
19%
Flow Cytometry
13%
Caco-2
13%
Rigor
13%
Upper Respiratory Tract Infection
13%
Vascularity
13%
Body Position
13%
Respiratory Tract Inflammation
13%
Diabetes Mellitus
13%
Inflammatory Mediator
13%
Diabetes
13%
Adhesive Agent
13%
Incubation
13%
Body Weight
13%
Vascular Disease
13%
In Vitro
13%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Virus RNA
13%
Virus Replication
13%
Breathing
13%
Lung Lavage
13%
Vasculitis
13%
Inflammatory Cytokine
13%
Serositis
13%
Real-Time Polymerase Chain Reaction
13%
Immobility
13%
Plaque Assay
13%
Lipid Binding Protein
13%
K 18
13%
Hexachlorophene
13%
Virus Entry
13%
Influenza A Virus (H1N1)
7%
Mixed Infection
6%
Influenza A (H1N1)
6%
Quantitative Reverse Transcription Polymerase Chain Reaction
6%
Keyphrases
Adverse Outcomes
100%
Patients with Diabetes
100%
COVID-19 Patients
100%
Hamster
75%
Spike Protein
53%
Protein Binding
39%
Viral Infection
35%
Annexin V
28%
Illness
21%
Microvessels
21%
Virus
17%
Adhesion
14%
Serial Dilution
14%
Angiotensin-converting Enzyme 2 (ACE2)
14%
Cellular Internalization
14%
Pneumonia
14%
Post Inoculation
10%
Inoculation
10%
TCID50
10%
Pre-coating
10%
Diabetic
10%
Human Influenza
10%
Quantitative PCR
10%
Immobility
7%
Rectal Swab
7%
Transfusion
7%
Clinical Symptoms
7%
Cytokine Analysis
7%
Inflammatory Mediators
7%
Diabetes
7%
Plaque Assay
7%
Upper Respiratory Tract Infection
7%
Lung Homogenate
7%
Tissue Culture
7%
Mechanistic Studies
7%
Viral Replication
7%
Syrian Hamster
7%
Sham Control
7%
Lipid-binding Protein
7%
Non-diabetic
7%
Caco-2 Cells
7%
Inflammatory Cytokines
7%
COVID-19 Outcomes
7%
Twice a Day
7%
Labored Breathing
7%
Adhesive Surface
7%
Vascular Inflammation
7%
Drug Development
7%
Influenza
7%
Infection Control
7%
Novel Therapeutic Targets
7%
Commercially Available Kit
7%
Inflammation
7%
Lung Tissue
7%
Therapeutic Development
7%
Perfusion
7%
Bronchoalveolar Lavage
7%
Influenza-like Illness
7%
Oral Swab
7%
Mechanistic Evidence
7%
Vasculature
7%
COVID-19
7%
Incubation
7%
Between-group
7%
Infection Outcome
7%
Therapeutic Agents
7%
Quality Differences
7%
Virus Entry
7%
ID50
7%
Microfluidics
7%
Up to Five
7%
Peripheral Tissues
7%
Viral RNA Levels
7%
Infectious Dose
7%
Confocal Image
7%
Flow Cytometry
7%
Euthanized
7%
GFP Fluorescence
7%
Viral Stock
7%
Inflammatory Response
7%
Airway Inflammation
7%
Plasma Volume
7%
Histology
7%
Novel Mechanism
7%
PCR Assay
7%
Clinical Signs
7%
Vascular Pathology
7%
Supernatant
7%
Pharmacology, Toxicology and Pharmaceutical Science
Protein S
100%
Microparticle
100%
Adverse Outcome
100%
Virus Infection
66%
Infection
58%
Cytokine
53%
Lipocortin 5
53%
Diseases
40%
Inflammation
26%
Phosphatidylserine
26%
Influenza
19%
Respiratory Tract Inflammation
13%
Vascular Disease
13%
Diabetes Mellitus
13%
Rigor
13%
Virus RNA
13%
Immobility
13%
Syrian Hamster
13%
Flow Cytometry
13%
SARS Coronavirus
13%
Upper Respiratory Tract Infection
13%
Drug Development
13%
Adhesive Agent
13%
Hexachlorophene
13%
Hamster Model
13%
Vasculitis
13%
K 18
13%
Lipid Binding Protein
13%
Influenza A Virus (H1N1)
7%
Influenza A (H1N1)
6%
Mixed Infection
6%